Forte Biosciences
FBRX
61 hedge funds and large institutions have $51.5M invested in Forte Biosciences in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 18 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
41% more call options, than puts
Call options by funds: $768K | Put options by funds: $545K
5% more funds holding
Funds holding: 58 → 61 (+3)
0.01% less ownership
Funds ownership: 0.08% → 0.07% (-0.01%)
31% less capital invested
Capital invested by funds: $74.7M → $51.5M (-$23.2M)
33% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$608K |
| 2 |
6CM
683 Capital Management
New York
|
+$487K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$483K |
| 4 |
State Street
Boston,
Massachusetts
|
+$282K |
| 5 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$176K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.62M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.69M |
| 3 |
JP Morgan Chase
New York
|
-$1.88M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$326K |
| 5 |
BP
BBR Partners
New York
|
-$267K |
FBRX Hedge Fund Activity: Q2 2018 in Review
61 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q2 2018, worth a combined $51.5M — down 31% from $74.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new FBRX positions and 3 closed out — a net gain of 3 holders — while 12 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $608K. The largest seller was T. Rowe Price Associates, cutting an estimated $4.62M.
- 61 institutional investors held Forte Biosciences (FBRX) as of Q2 2018, up from 58 in Q1 2018.
- Funds reported $51.5M of Forte Biosciences stock for Q2 2018, down 31% quarter-over-quarter.
- 6 funds opened new Forte Biosciences positions in Q2 2018 and 3 closed out, a net change of +3 holders.
- The largest Forte Biosciences buyer in Q2 2018 was BlackRock, an estimated $608K added.
- The largest Forte Biosciences seller in Q2 2018 was T. Rowe Price Associates, an estimated $4.62M sold.
Based on aggregated 13F filings for Q2 2018.